Experience iStent Technology for Glaucoma Treatment at B B Eye Foundation

Experience iStent Technology for Glaucoma Treatment at B B Eye Foundation

Kolkata, West Bengal – B B Eye Foundation, has been one of the pioneering institutions to begin Phacoemulsification and LASIK in Eastern India, home to excellence in eyecare for the last 34 years. Today, for the benefit of our cataract and glaucoma patients we share the introduction of iStent Inject and iStent Inject W technology.

Surgery in Glaucoma

Glaucoma is a disease of the eye where progressive rise in eye pressure leads to loss of vision. It is often called the ‘silent theft of vision’ as it does not present with any symptoms during the early stages of the disease. Micro Invasive Glaucoma Surgery (MIGS), is the latest advancement in the surgical management of glaucoma to reduce the burden of the disease. Patients with glaucoma are often weighed down by multiple drops at specific intervals. Traditionally only patients with uncontrolled eye pressure glaucoma have been advised for glaucoma surgeries. With the iStent technology in the arsenal, patients with mild to moderate glaucoma may be treated with a fifteen minute procedure to allow them to become medication free.

Dr. Chandrima Paul’s performs East India’s first iStent Inject procedure.

Benefits of iStent technology for patients:

  1. High safety profile compared to older microinvasive glaucoma surgeries
  2. Minimal postoperative discomfort with quick recovery
  3. Fewer and less frequent postoperative check ups
  4. Suitable for patients with early glaucoma
  5. Lesser impact on quality of life

When you have glaucoma and cataract

Additionally, a boon for this procedure is the ability for surgeons to perform it as a combined procedure for patients with glaucoma undergoing cataract surgery with high safety and efficacy. Patients with early glaucoma on 1-2 anti-glaucoma medications who develop cataract have performed exceedingly well following cataract surgery and iStent implantation, making them medicine free postoperatively.

Dr. Anujeet Paul, implants his first iStent Inject and shares the ease of use of the device.

Expert endorsements

Dr. Chandrima Paul was the first surgeon in Eastern India to implant the iStent Inject in December 2022 and has subsequently incorporated this procedure in her three decade long clinical practice.

Dr. Sumit Chowdhury has also shared his experience with the iStent Inject and mentions that it shows incredible promise for his patients with glaucoma on one or two medications.

Dr. Anujeet Paul who recently implanted the iStent Inject has highlighted its ease of use and high safety profile. He adds that it will be a boon with cataract patients with early glaucoma looking to let go of all medication post surgery.

About B B Eye Foundation

B B Eye Foundation is a 34 year old institution that has been on the forefront of transformational eye care in Eastern India. With the commitment to serve with expertise, technology and humanity, the institution has been the first to revolutionise cataract surgery with phacoemulsification and LASIK surgery with Femto LASIK and Contoura Vision Technology. Today, it is home to Premium Cataract Surgery with Multifocal, Toric and EDOF IOLs, Glaucoma Surgery with MIGS, Vitreoretinal Surgery and MIVS.

Advancements in iStent Inject Technology Revolutionize Glaucoma Treatment

Advancements in iStent Inject Technology Revolutionize Glaucoma Treatment

Kolkata, West Bengal – Disha Eye Hospitals, a leader in ophthalmic care and innovation, is thrilled to announce significant advancements in the iStent Inject technology. This groundbreaking development is set to revolutionize the treatment of glaucoma, a leading cause of irreversible blindness globally. Committed to enhancing patient outcomes and quality of life, Disha Eye Hospitals remains at the forefront of introducing cutting-edge medical technologies.

Revolutionizing Glaucoma Treatment

Glaucoma affects millions of people worldwide, leading to gradual vision loss due to increased intraocular pressure (IOP). Traditional treatments often involve the prolonged use of eye drops or invasive surgeries, both of which can be burdensome and carry significant risks. The iStent Inject, a micro-invasive glaucoma surgery (MIGS) device, offers a minimally invasive alternative that effectively reduces IOP, providing a more manageable solution for glaucoma patients.

Advancements in iStent Inject Technology

The latest advancements in iStent Inject technology incorporate several key improvements:

  1. Enhanced Biocompatibility: iStent Inject is crafted from advanced materials that are biocompatible, reducing the risk of adverse reactions and improving long-term patient outcomes.
  2. Optimized Design: The redesigned stent features a smaller size and an ergonomic shape, allowing for easier implantation and better integration with the eye’s natural anatomy.
  3. Improved Efficacy: Clinical trials have demonstrated that the iStent Inject significantly lowers IOP more consistently compared to previous models, offering patients reliable solution for managing their glaucoma.
  4. Simplified Procedure: The implantation process has been refined to be even less invasive, shortening recovery times and reducing the overall risk of complications.

Advantages for Patients

The iStent Inject technology provides several advantages for patients, making it a superior choice for glaucoma treatment:

  • Painless and Sutureless: The procedure is minimally invasive, causing minimal discomfort to patients. It does not require sutures, resulting in a quicker, more comfortable recovery.
  • Combined with Cataract Surgery: The iStent Inject can be conveniently implanted during cataract surgery, allowing patients to address both conditions simultaneously. This combination reduces the number of surgical procedures and recovery periods.
  • Micro Incision: The device is implanted through a micro incision, minimizing trauma to the eye and significantly reducing recovery time.
  • Insurance and Cashless Facility: The iStent Inject procedure is covered under many insurance plans, offering patients the convenience of cashless treatment options at Disha Eye Hospitals. This makes advanced glaucoma care accessible and affordable.

Clinical Success and Patient Impact

The advancements in iStent Inject technology have been validated by extensive clinical research. Recent studies reveal that patients experience a marked reduction in IOP, leading to a decreased need for additional medications and a lower risk of glaucoma progression. Moreover, the simplified procedure has made it accessible to a broader range of patients, including those who may not be candidates for more invasive surgeries.

Expert Endorsements

Dr. Dipanjan Pal, a leading ophthalmologist at Disha Eye Hospitals, shared his insights: “The advancements in iStent Inject technology represent a significant leap forward in our ability to treat glaucoma effectively. This minimally invasive device offers our patients a safer, more efficient option to manage their condition and preserve their vision and minimises the need for multiple topical antiglaucoma medicines. The biocompatibility and improved design have translated into better patient outcomes and a smoother recovery process.”

Dr. Arijit Mitra, another esteemed ophthalmic surgeon at Disha Eye Hospitals, echoed these sentiments: “We have seen remarkable results with the 2nd Gen iStent Inject. Our patients report a substantial improvement in their quality of life due to the reduced dependency on daily eye drops and the minimized risk of complications associated with traditional surgeries. This technology truly embodies the future of glaucoma treatment.”

Dr. Suchanda Sar, one of the renowned Glaucoma Surgeon at Disha Eye Hospital said “This innovative therapy has changing the paradigm in the management of glaucoma”.

About Disha Eye Hospitals

Disha Eye Hospitals is dedicated to pioneering innovative solutions in ophthalmology. With a commitment to excellence and a focus on improving patient care, we continue to lead the way in developing and implementing cutting-edge technologies that address the most pressing challenges in eye health. Our team of highly skilled and experienced ophthalmologists ensures that patients receive the best possible care with the most advanced treatments available.

For more information about the iStent Inject technology and our ongoing efforts to combat glaucoma, please visit Disha Eye Hospital.

About iStent Inject W

The iStent Inject W is a tiny implantable device designed to create a permanent pathway through the trabecular meshwork, improving aqueous humor outflow and lowering intraocular pressure in patients with glaucoma. It represents a significant advancement in minimally invasive glaucoma surgery, offering a safer and more effective treatment option.

Disha Eye Hospitals continues to be at the forefront of ophthalmic innovation, providing solutions that make a tangible difference in patients’ lives. The latest advancements in iStent Inject W technology underscore our commitment to excellence and our vision for a world where no one has to suffer from preventable blindness.